All In MedTech

Device Trial Radar · NCT07645820

Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares

Evaluation of a Non-Invasive Device for Early Detection of Flares in Adults and Adolescents With Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

450

Planned (sponsor's estimate)

Start

Jun 4, 2026

Primary completion

Apr 1, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Castle Biosciences IncorporatedNot on our public-company list
Sponsor type
Industry
Collaborators
SciBase AB
First posted
Jun 12, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 12 years, up to 89 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device. Participants aged 12 to 89 years with a history of AD flares will use the device at home for about 90 days. Participants will complete device measurements, electronic diary entries, and up to five in-person study visits. The study is based on the idea that changes in skin barrier function may occur before an AD flare becomes visible or symptoms begin. Information collected during the study, including device measurements, diary entries, and investigator assessments, will be used to evaluate whether these changes may help estimate the likelihood of an AD flare before visible signs or symptoms occur.

Conditions

  • Atopic Dermatitis

Interventions

  • Nevisense electrical impedance spectroscopyDevice

    The NevisenseGo device will collect skin measurements from people with atopic dermatitis (AD) to see if it can effectively predict a flare in disease.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relationship between skin measurements and subsequent atopic dermatitis flaresTime frame: Measurements taken over 90 days, 5 days a week
  2. Develop and validate an algorithm using Nevisense Go EISTime frame: From enrollment until end of treatment at 90 days.

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • U.S. Dermatology Partners

    Phoenix, Arizona · Recruiting

  • James Y. Wang MD, Inc

    Los Angeles, California · Recruiting

  • True Blue Clinical Research

    Tampa, Florida · Recruiting

13 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.